Abstract
Classical antimicrobial drugs target proliferation and therefore place microbes under extreme selective pressure to evolve resistance. Alternative drugs that target bacterial virulence without impacting survival directly offer an attractive solution to this problem, but to date few such molecules have been discovered. We previously discovered a widespread group of bacterial adhesins, termed Multivalent Adhesion Molecules (MAMs) that are essential for initial binding of bacteria to host tissues and virulence. Thus, targeting MAM-based adherence is a promising strategy for displacing pathogens from host tissues and inhibiting infection. Here, we show that topical application of polymeric microbeads functionalized with the adhesin MAM7 to a burn infected with multidrug-resistant Pseudomonas aeruginosa substantially decreased bacterial loads in the wound and prevented the spread of the infection into adjacent tissues. As a consequence, the application of this adhesion inhibitor allowed for vascularization and wound healing, and maintained local and systemic inflammatory responses to the burn. We propose that MAM7-functionalized microbeads can be used as a topical treatment, to reduce bacterial attachment and hence prevent bacterial colonization and infection of wounds. As adhesion is not required for microbial survival, this anti-infective strategy has the potential to treat multidrug-resistant infections and limit the emergence of drug-resistant pathogens.
Burns contribute to a major fraction of trauma injuries and many trauma-associated fatalities occur in burn patients. In the United States alone, there are over a million burn injuries, leading to 100,000 hospitalizations annually1. As the skin is the body’s first and major defense mechanism against microbial intrusion, patients enduring burn trauma are particularly susceptible to infections. Immediately following injury, the body responds with systemic immunosuppression2,3. Up to 75% of the mortality in burn patients is associated with an infection, particularly in patients suffering severe burns of 40% total body surface area or above.
Sepsis and graft rejection are dangerous clinical outcomes for patients with burn wound infections. Although immediate care for burn patients has improved due to treatments such as hemodynamic stabilization4,5, more strategies to minimize burn wound infections are urgently needed to reduce patients’ morbidity and mortality. With the increase in antibiotic resistant bacteria and the narrowing pipeline for developing new antimicrobials, the challenges for treating infection are ever more difficult6.
Bacterial infections in burn patients are one of the most common causes of mortality. The Gram-negative bacterium Pseudomonas aeruginosa is frequently associated with hospital acquired infections7,8 and is found in approximately 33% of all burn wounds and in 59% of extensive burns1. Due to drug efflux mechanisms and genetically acquired drug resistance, P. aeruginosa is extremely antibiotic tolerant9. These characteristics have led to the rise of multidrug-resistant isolates that are observed in burn patients and transferred between patients through healthcare personnel or hospital equipment10,11. The intrinsic modes of bacterial defense allow for their persistence in clinical settings and current treatments that use more antibiotics are resulting in increasing antimicrobial resistance.
It is now globally recognized that there is an urgent need for new antimicrobial drugs. However, antimicrobials that prevent replication exert strong selective pressure, leading to the rapid acquisition of resistance and thus new antimicrobials that target microbial virulence, rather than growth, are an attractive therapeutic option. Finally, these new drugs should allow for normal wound healing in the patient12,13. Although anti-virulence drugs have been an emerging concept for the last 50 years, to date very few have been tested for their efficacy in infection models14,15 and none are capable of targeting a broad spectrum of pathogens13. Here we provide evidence that microbeads functionalized with MAM7 adhesin meet the criteria for such a “new antimicrobial”.
MAM7 is a bacterial outer membrane protein that promotes host cell adhesion by a wide range of Gram-negative bacteria16. Previously, in vitro studies demonstrated that recombinant MAM7 prevents Gram-negative pathogens and methicillin resistant Staphylococcus aureus from binding to host cells, thereby inhibiting subsequent infection and cytotoxicity. We also reported that the binding avidity, and thus competitive effect of MAM7 could be drastically increased by multivalent surface display17,18,19,20. To our knowledge, MAM7 is the first reported virulence-targeting compound with a broad spectrum activity. Preliminary cell culture studies showed that treatment with recombinant MAM7 does not interfere with cellular processes involved in wound healing, such as proliferation, extracellular matrix deposition, and migration17. Based on these promising traits, we set out to test the efficacy of MAM7 as a potential inhibitor of multidrug-resistant P. aeruginosa in a murine burn and excision infection model. We found that microbeads functionalized with MAM7 adhesin act as an ideal antimicrobial agent that could potentially bring down bacterial colonization in a burn patient to a sub-lethal level.
Results
A bacteriomimetic inhibitor based on the adhesin MAM7 decreases bacterial burden on burn wounds
The adhesin MAM7 is an outer membrane protein that is widely expressed by Gram-negative pathogens. It consists of seven protein domain repeats that are responsible for attachment to host cells during an infection. A recombinant fragment of MAM7 containing these repeats is expressed as a Glutathione-S-Transferase (GST) fusion protein, GST-MAM7. Purified, recombinant GST-MAM7 is chemically coupled to a micron-sized, spherical polystyrene scaffold and this composition provides a mimic for its endogenous presentation on the surface of a bacterium (Fig. 1). Multivalent surface display significantly enhances binding avidity and thus, the material’s competitive effect against pathogens (Hawley et al.17). GST-MAM7 functionalized beads and control microbeads functionalized with only GST were synthesized on a milligram scale and tested in a quality control inhibition assay using an in vitro infection model as previously described17,18,19,20.
To assess whether GST-MAM7 beads could decrease the bacterial load in burns, we used a burn and excision infection rat model. For severe burns, early excision, followed by application of wound dressings and/or grafting is currently the standard of care1. Early surgical excision to remove necrotic tissue within the first few days following injury is routinely used in treatment of extensive burns, and has significantly contributed to decreased occurrence of burn wound sepsis and improved survival21,22. For this study, dorsal burn wounds covering 40% of the total body surface area were induced onto the back of adult rats and two days after injury, eschar tissue was surgically excised (Fig. 2A)23. Excision prior to treatment with the MAM7 inhibitor increased the treatment efficacy, compared to unexcised, necrotic burns (Fig. 3). Coincidently, on day two, a suspension of 5·106 CFU of P. aeruginosa Xen5, a bioluminescent derivative of a multidrug-resistant septicemia blood isolate24, were introduced into the excision. Suspensions containing 3·108 GST beads or GST-MAM7 beads in saline were applied topically to the wound bed at the same time and, then, applied every 24 hours after excision. The bacterial loads of the infection were monitored by biophotonic imaging over 6 days (Fig. 2A).
In the infection that was treated with control GST beads, the bacteria were initially constrained to the edge of the surgical excision, but gradually spread across the entire burn area over the course of 6 days (Fig. 2B). By contrast, in wounds treated with GST-MAM7 beads, the bacteria remained on the edge of the wound (Fig. 2B). Over the first 24 hours, GST-MAM7 bead treatment reduced the bacterial burden below the initial inoculum and, then, remained lower than the control treatment for an additional three days. In control treated animals, the bacterial burden increased approximately 10-fold over the course of the 6 day experiment (Fig. 2C). Treatment with the MAM7 inhibitor beads significantly decreased bacterial colonization of the burn for four days following infection when compared to mock treatment, although leveled off towards the end of the experiment. These studies demonstrate that fresh wounds can be treated with GST-MAM7 functionalized beads as an early intervention and the bacterial load will be reduced in the excision and surrounding burnt area (Fig. 2).
Treatment of excised burn wounds with GST-MAM beads decreases bacterial spread
We considered the possibility that the anti-adhesion activity of MAM7 may simply displace burn-colonizing bacteria to adjacent tissue sites. To address this, we used biophotonic imaging to follow the spread of the infection over the wounded area (Fig. 2D; the peaks represent bacterial burden across the wound). In the control animals treated with GST-beads, we observed a gradual spread of bacteria (light blue to dark blue) over the wound during the course of the 6 day experiment. By contrast, in the GST-MAM7 bead treated animals, the spread and amount of bacterial colonization (pink to red) is substantially lower during the experimental time course. This demonstrates that GST-MAM7 beads not only lower the total bacterial burden in the wound, but spatially confine bacterial colonization and inhibit the spread of infection.
Beads functionalized with MAM7 adhesin do not perturb angiogenesis or wound closure
Antimicrobial treatments for wounds must not impair the natural wound healing process. Thus, to assess the impact of GST-MAM7 beads on vascularization and wound closure, we analyzed H&E sections of burned tissue on day 6 of the infection. In Fig. 4A, a section of skin containing a burn is shown in three parts: 1. unburned, normal tissue; 2. burned tissue with eschar intact; 3. burned tissue with the eschar excised. Analysis of an uninfected tissue sample from the burned tissue with the eschar excised shows normal granulation, vascularization and initiation of wound healing (Fig. 4A). When the GST-beads or GST-MAM7 beads are applied to the burned tissue with the eschar excised, similar granulation, vascularization and initiation of wound healing is observed (Fig. 4C and D). Therefore, the beads alone did not disrupt normal healing. Burned tissue with the eschar excised that was treated with P. aeruginosa and the GST-beads or GST-MAM7 beads also appeared to heal in a normal manner (Fig. 4E and F). Further quantitative analysis of wound closure revealed no significant differences in healing between GST-beads or GST-MAM7 beads treated groups, with excision areas decreasing by approximately 22 and 30%, respectively, over 6 days (Fig. 4G). Thus, MAM7 bead treatment does not impair normal burn wound healing.
Normal neutrophil infiltration of burned skin is observed in GST-MAM7 bead treatment
Severe burns generally elicit a strong inflammatory response, both locally and in the tissues adjacent to the burn25. A moderate pro-inflammatory response encourages wound healing, but an excessive inflammatory response leads to organ damage and dysfunction26. We therefore tested if application of control beads or adhesin beads to burns without and with P. aeruginosa would have an effect on local inflammation. Adjacent sections of tissues shown in Fig. 3 were used to assess neutrophil infiltration. In untreated animals, a normal migration of neutrophils moving toward the wounded surface area is observed (Fig. 5).
In addition, as observed with the green channel background, vascularization is occurring in the healing tissue (Fig. 6A). The application of GST beads or GST-MAM7 beads to uninfected or P. aeruginosainfected burned and excised wounds did not lead to a change near newly formed blood vessels (Fig. 6A–E) or neutrophil migration towards the wound (Figs 5A–E and 6A–E). Overall, the observation that GST-MAM7 does not hinder wound healing are consistent with our in vitro infection studies showing that, despite MAM7 binding to host surface receptors including fibronectin27, MAM7 inhibitor treatment does not interfere with processes intimately associated with wound healing, including proliferation and extracellular matrix formation17.
Figure 6
Application of adhesin functionalized beads does not alter systemic inflammatory reponsens
Although wound healing was visually normal in adhesin-bead treated wounds, we considered the possibility that the application of these beads may provoke a systemic inflammatory response that could be deleterious to the host. We therefore tested levels of circulating serum cytokines in the test animals. However, in all cases animals that were untreated or treated with GST beads or GST-MAM7 beads expressed similar levels of circulating serum cytokines (Fig. 5F). In animals infected with P. aeruginosa, the induction of circulating serum cytokines was unaltered by application of MAM7 adhesin beads, compared to control beads (Fig. 5G). Therefore, the application of MAM7 inhibitor to P. aeruginosainfected wounds did not alter systemic inflammatory responses.
Discussion
Taken together, our data demonstrate for the first time, the efficacy of a virulence-targeting antimicrobial compound with broad specificity in an in vivo model. Microbeads functionalized with a recombinant fragment of the adhesin MAM7 fulfill the requirements for new strategies to combat pathogens in a particularly challenging clinical setting: deep tissue burns. First, the MAM7-mimicking inhibitor competes with the pathogen for sites on the host to colonize and initiate an infection. The success of this competition depends on the availability of native receptors on the host cell surface (compare Figs 2 and and3).3). As this mechanism of inhibition targets host colonization, but is non-essential for the pathogen’s survival, there is likely less evolutionary selection for a mechanism of resistance. Second, the bacteriomimetic inhibitor does not have any deleterious impact on wound healing, making it an excellent candidate for future use on patients. Third, there is no enhanced inflammatory response to MAM7 inhibitor treatment. We rationalize this is because hosts (patients) are immunotolerant to MAM7-like molecules because they have been exposed to MAMs displayed by commensal bacteria throughout development20. Therefore, as expected, the host does not mount an altered local or systemic immune response to GST-MAM7 beads. The inflammatory response to the infection was not significantly elevated compared to burnt, uninfected animals. This is likely because of the limited potential of the P. aeruginosa strain used to invade host tissues and spread systemically. The absence of systemic spread was underpinned by the absence of systemic bioluminescence, even at high exposure settings, and by the absence of clinical signs of sepsis in all animals. Future work will address if this treatment is efficacious for the treatment of invasive infections as well.
The treatment with GST-MAM7 beads was highly efficacious, and decreased the bacterial burden significantly for four days following infection. This is likely due to the limited potential of displaced bacteria to grow and persist in the exudate, compared to bacterial in direct contact with the tissue. The beneficial effect of treatment for the infected host may be underestimated by measuring bacterial burden, due to the fact that bacteria displaced from the tissue are partially trapped in the wound exudate crust, and not completely removed from the wound, so that they still contribute to luminescence. Future work will attempt to better discriminate between directly attached bacteria, and bacteria which are displaced from the tissue but retained in the semi-solid exudate matrix covering the wound bed, by measuring luminescence before and after exudate removal. However, the pathogenic potential of displaced bacteria is significantly reduced compared to bound bacteria, since many virulence factors, such as transfer of effectors via type III secretion stems, rely on intimate contact between bacterium and host cell16,28. Although bacteria are not eradicated from the wound site by MAM7 beads, such a treatment creates a therapeutic window that slows the progress of bacterial colonization and infection, even under the high bacterial burden used in the study. An altered dosing schedule with higher concentrations and more frequent applications of GST-MAM7 beads over the first 24–48 hours following infection might reduce bacterial colonization further. Alternatively, this strategy may be combined with other, classical, antimicrobials to improve clinical outcomes, and such combination therapies have now become the standard for treatment of infectious and non-infectious diseases alike29,30.
In conclusion, we have demonstrated that a biological agent with a broad spectrum activity, GST-MAM7 beads, targets bacterial adherence to reduce lethal pathogen infection in vivo. These findings demonstrate the potential of compounds targeting virulence traits in combating drug- resistant infections, and potentially limiting the rapid expansion of resistant bacterial populations.
Methods
Bacterial strains and growth conditions
Pseudomonas aeruginosa Xen5, a bioluminescent derivative of a blood isolate from a septic patient (strain ATCC 19660), was used throughout the experiments. The strain is resistant to carbenicillin, chloramphenicol, tetracycline and trimethoprim by Kirby-Bauer Disk Diffusion Test. P. aeruginosa was grown in LB broth at 37 °C under constant aeration. Bacteria was grown in log-phase to an optical density of 1.0. Bacteria suspended in LB media was introduced directly into the wound via pipette.
Synthesis of functionalized microbeads
The adhesin MAM7 (VP1611)ΔN44 was expressed with an N-terminal GST-tag, and purified by glutathion affinity purification, gelfiltration and ion exchange chromatrography, as previously described16. Purified GST-MAM7ΔN44 or GST alone were chemically coupled to polystyrene microbeads, as previously described31, to produce inhibitor and control beads, respectively.
Animal protocols, burn and excision model
All animal protocols were reviewed and approved by the University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee. All experiments were performed in accordance with relevant guidelines and regulations.
Adult male Sprague-Dawley rats (276–300 g) were obtained from Harlan Laboratories (Houston, TX). Animals were acclimated in house for seven days after arrival at UTSW. During acclimation rats had access to ad libitum commercial rat chow and water. Rats were housed under a 12 hour light/dark cycle. After acclimation, rats were individually housed for the remainder of the experiment. Rats were deeply anesthetized with isoflurane. While under anesthesia, the area to be burned was shaved. Rats were then secured in a constructed template device. The skin exposed through the template was immersed in 100 °C water for 12 s on the back and upper sides of the body to produce full-thickness cutaneous burns over 40% total body surface area. This burn technique produced complete destruction of the underlying neural tissue. After immersion, the rats were immediately dried and fluid resuscitated. All burned animals received standard fluid resuscitation consisting of 4 ml/kg per percentage burn Lactated Ringer’s solution (~50 ml) given intraperitoneally immediately after completion of the burn injury. All burned rats were given analgesics for pain control (buprenorphine 0.5 mg/kg) immediately after injury and 12 hours post injury. After 12 hours post injury, analgesics were administered as needed.
One set of experiments was conducted to compare the efficacy of inhibitor and mock treatment in non-excised burns (n = 6 animals for the treatment and control group, respectively). In both groups, 5·106 CFU of P. aeruginosa Xen5 was directly applied to the wound 1 day after introducing the burn, followed by topical application of suspensions containing 3·108 inhibitor or control beads in saline every 24 hours.
For the burn excision model, burns were introduced as above and part of the eschar tissue corresponding to an area of approximately 4×4 cm was removed by surgical excision to the fascia. 5·106 CFU of P. aeruginosa Xen5 was directly applied to the wound immediately following excision, followed by topical application of suspensions containing 3·108 inhibitor (n = 12 animals) or control beads in saline (n = 10 animals) every 24 hours. Animals were imaged daily, using an IVIS Spectrum In vivo Imaging System (Perkin Elmer). Animals were sacrificed if they became moribund, or at the end of the experiment (6 days post infection). At the end of the experiment, animals were euthanized under isoflurane anesthesia. Blood and tissue were collected from each animal immediately post-mortem. Serum was aliquoted into cryovials and stored at −80 C for cytokine analysis. All experiments were performed in accordance with relevant guidelines and regulations.
Tissue preparation and histology
A portion of the dorsal skin was fixed overnight in 10% neutral buffered formalin (NBF) and paraffin embedded. Tissue sections (5 μm) were deparaffinized and rehydrated using graded alcohol concentrations followed by H&E staining or immunofluorescence staining. For IF staining, formalin-fixed and paraffin embedded skin tissue sections were deparaffinized in xylenes and rehydrated using graded alcohol concentrations. Samples were then boiled in 10 mM citric acid for 20 min to retrieve epitopes. Sections were permeabilized with 1% Triton X-100 and blocked with 2% BSA in PBS-T. Primary antibody incubation (anti-myeloperoxidase, 1:100, Abcam ab9535) was carried out overnight at 4 °C in PBS-T + 1% BSA, and secondary antibody incubation (anti-rabbit Alexa-488, 1:500, ThermoFisher A-11034) was performed over 1 h at room temperature. Sections were finally stained for DNA using Hoechst (ThermoFisher, 33342) and mounted (Prolong gold antifade, ThermoFisher P36930). Fluorescence images were acquired on a Zeiss LSM710 confocal microscope and processed using Image J and CorelDraw X5.
Analysis of serum cytokine levels
Serum cytokines were analyzed with Bio-Plex Pro Rat Cytokine TH1/TH2 panel according to the manufacturer’s recommended protocol with the Bio-Plex MAGPIX Multiplex Reader (Bio-Rad, Hercules, California). Data was analyzed with the Bio-Plex Data Pro software.
Image analysis
To analyze spatial spread of infections, intensity matrices were extracted from luminescence images using MetaMorph software (Molecular Devices). Intensity data was integrated separately for each pixel row, and integrated intensity profiles were transformed to normalize midpoints of excisions to y = 0. Data sourced above and below the midpoints were expressed as positive and negative y-values, respectively.